Lit Matters #3: Should we regularly check troponins in patients with SVT?

Supraventricular tachycardia often produces symptoms that overlap with acute coronary syndrome, but SVT itself is not usually an ischemic arrhythmia. Troponin elevation is common in SVT, especially with high-sensitivity assays, yet current evidence does not link that finding to meaningful increases in CAD or major adverse cardiac events.

Troponin Testing in SVT

• Common biomarker elevation: Troponin rises are frequent in SVT, with a pooled prevalence of 46%, so a positive result alone has poor specificity for acute coronary syndrome in this rhythm.
• Low MACE signal: Major adverse cardiac events were uncommon overall at about 6%, supporting the idea that uncomplicated SVT carries a low baseline ischemic event rate rather than a troponin-driven one.
• Poor prediction of CAD: Elevated troponin in SVT was not associated with subsequent CAD or MACE, making routine testing a low-yield strategy unless other cardiovascular risk factors change the picture.
• High-sensitivity assay effect: Studies using high-sensitivity troponin were more likely to detect elevations, a reminder that newer assays amplify biologic signal without necessarily improving clinical decision-making in SVT.
• Testing downstream consequences: Additional cardiac testing was infrequent and only occasionally clinically significant, a useful point when deciding whether a positive troponin should trigger more workup. We get into the practical ordering implications in the episode.